Effects of cyclosporin on joint damage in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 15, Issue SUPPL. 17, 1997, Pages

  Ferraccioli, G F ^a   Bambara, L M ^b   Ferraris, M ^c   Perpignano, G ^b   Cattaneo, R ^b   Porzio, F ^b   Accardo, S ^b   Mattara, L ^b   Zoppini, A ^b   Benucci, M ^b   Ostuni, P A ^b   Pasero, G ^b  

^a UNIVERSITY OF UDINE   (Italy)

^b Hospitals of Vercelli ^*

^c Hospitals of Vercelli   (Italy)

Author keywords

Cyclosporin; Joint damage; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; CYCLOSPORIN; GOLD; METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; BONE NECROSIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG EFFICACY; DRUG MECHANISM; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; ARTHROGRAPHY; CLINICAL TRIALS; CYCLOSPORINE; HUMANS; JOINTS; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 0030741854     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. EDMONDS JP, SCOTT DL, FÜRST DE, BROOKS P, PAULUS HE: Antirheumatic drugs: a proposed new classification. Arthritis Rheum 1993; 36: 336-9.
2. KUSHNER I, DAWSON NV: Changing perspectives in the treatment of rheumatoid arthritis. J Rheumatol 1992; 19: 1831-4.
3. YELIN E, MEENAM R, NEVITT M, EPSTEIN W: Work disability in rheumatoid arthritis. Effects of disease, social and work factors. Ann Intern Med 1980; 93: 551-6.
4. MAKISARA GL, MAKISARA P: Prognosis of functional capacity and work capacity in rheumatoid arthritis. Clin Exp Rheumatol 1982; 1: 117-25.
5. CASH JM, KUPPEL JH: Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994; i: 1368-75.
6. PAULUS HE, BULPITT KJ: DC-ART classification: review of relevant clinical studies. J Rheumatol 1994; 21 (Suppl. 41): 8-22.
7. FIRENSTEIN GS, PAINE MM, BOYLE DL: Mechanism of methotrexate action in rheumatoid arthritis. Selective decrease in collagenase expression. Arthritis Rheum 1994; 37: 193-200.
8. KAYE JJ: Radiographic methods of assessment (scoring) of rheumatic disease. Rheum Dis Clin North Am 1991; 17:457-70.
9. BROWER AC: Use of the radiograph to measure the course of rheumatoid arthritis. Arthritis Rheum 1990; 33: 316-24.
10. VAN DER HEIJDE DMFM: Plain X-rays in rheumatoid arthritis. Overview of scoring methods, their reliability and applicability. Baillière's Clin Rheumatol 1996; 10: 435-53.
11. SHARP JT, LIDSKY MD, COLLINS LC, MORELAND J: Methods of scoring the progression of radiological changes in rheumatoid arthritis. Arthritis Rheum 1971; 14: 706-20.
12. LARSEN A, DALE K, EEK M: Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiologica (Diagn) 1977; 18: 481-91.
13. GUTH A, COSTE J, CHAGNON S, LACOMBE P, PAOLAGGI JB: Reliability of three methods of radiologic assessment in patients with rheumatoid arthritis. Invest Radiol 1995; 30: 181-5.
14. CUCHACOVICH M, COURET M, PERAY P, GATICA H, SANY J: Precision of the Larsen and the Sharp methods of assessing radiologic change in patients with rheumatoid arthritis. Arthritis Rheum 1992; 35: 736-9.
15. FERRACCIOLI GF, PRIOLO F, FERRARA R, DELLA CASA-ALBERIGHI O, MARUBINI E, PASERO G: Radiologic assessment of anatomic damage in RA. A contribution to a standardized approach in multicenter studies. Arthritis Rheum 1995; 38 (Suppl.): S330.
16. SHARP JT, WOLFE F, CORBETT M, ISOMAKI H, MITCHELL DM, FURST DE, SIBLEY J, SHIPLEY M: Radiological progression in rheumatoid arthritis: how many patients are required in a treatment trial to test disease modification ? Ann Rheum Dis 1933; 52:332-7.
17. ALARCÓN GS, LÓPEZ-MÉNDEZ A, WALTER J et al.: Radiographic evidence of disease progression in methotrexate treated and non-methotrexate disease modifying antirheumatic drug treated rheumatoid arthritis patients: a metaanalyis. J Rheumatol 1992; 19: 1868-73.
18. PAULUS HE, VAN DER HEIJDE DMFM, BULPITT KJ, GOLD RH: Monitoring radiographic changes in early rheumatoid arthritis. J Rheumatol 1996; 23: 801-5.
19. NORDSTROM DM, WEST SG, ANDERSEN PA, SHARP JT: Pulse methotrexate therapy in rheumatoid arthritis: a controlled prospective roentgenographic study. Ann Intern Med 1987; 107: 797-801.
20. JEURISSEN MEC, BOERBOOMS AMTH, VAN DE PUTTE LBA, DOESBURG WH, LEMMENS AM: Influence of methotrexate and azathioprine on radiologic progression in rheumatoid arthritis. A randomized, double-blind study. Ann Intern Med 1991; 114: 999-1004.
21. RAU R, HERBORN G, KARGER T, MENNINGER H, ELHARDT D, SCHMITT J: A double-blind comparison of parenteral methotrexate and parenteral gold in the treatment of early erosive rheumatoid arthritis: an interim report on 102 patients after 12 months. Semin Arthritis Rheum 1991; 21 (Suppl. 1): 13-20.
22. HERBORN G, RAU R, MENNINGER H, ELHARDT D, SCHMITT J: Data of two years of the comparative study methotrexate/aurothiomalate in 102 patients. Z Rheumatol 1992; 51: 163-71.
23. WEINBLATT ME, POLISSON R, BLOTNER SD, SOSMAN JL, ALIABADI P, BAKER N, WEISSMAN BN: The effects of drug therapy on radiographic progression of rheumatoid arthritis. Results of a 36-week randomized trial comparing methotrexate and auranofin. Arthritis Rheum 1993; 36: 613-19.
24. VAN DER HEIJDE DM, VAN RIEL PL, NUVER-ZWART IH, GRIBNAN FW, VAN DE PUTTE LB: Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989; 333: 1036-8.
25. PULLAR T, HUNTER JA, CAPELL HA: Effect of sulphasalazine on the radiological progression of rheumatoid arthritis. Ann Rheum Dis 1987; 46: 398-402.
26. VAN DER HEIJDE DMFM, VAN RIEL PLCM, NUVER-ZWART IH, VAN DE PUTTE LBA: Sulphasalazine versus hydroxychloroquine in rheumatoid arthritis: 3 year follow-up. Lancet 1989; 335: 539.
27. FØRRE Ø, and the NORWEGIAN ARTHRITIS STUDY GROUP: Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporin: results of a 48-week multicenter study comparing low-dose cyclosporin with placebo. Arthritis Rheum 1994; 37: 1506-12.
28. PASERO G. PRIOLO F, MARUBINI E et al.: Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996; 39: 1006-15.
29. FERRACCIOLI GF, DELLA CASA-ALBERIGHI O, MARUBINI E et al. on behalf of GRISAR (Gruppo Reumatologi Italiani Studio Artrite Reumatoide): Is the control of disease progression within our grasp ? Review of the GRISAR study. Br J Rheumatol 1996; 35 (Suppl. 2): 8-13.
30. PASERO G on behalf of GRISAR (Gruppo Reumatologi Italiani Studio Artrite Reumatoide): Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1995; 38 (Suppl.): S282 (Abstr. 777).
31. AN INTERNATIONAL CONSENSUS REPORT: The use of cyclosporin A in rheumatoid arthritis. Br J Rheumatol 1993; 32 (Suppl. 1): 1-3.
32. FERRACCIOLI GF on behalf of GRISAR (Gruppo Reumatologi Italiani Studio Artrite Reumatoide): The GRISAR study: assessment of side effects, withdrawals and survival on treatment after 24 months. Br J Rheumatol 1996; 35 (Suppl. 1): 215 (abstr. 415).